Tag: information

New York, N.Y., July 10, 2025 (GLOBE NEWSWIRE) -- NANO Nuclear Energy Inc. (NASDAQ: NNE) (“NANO Nuclear” or “the Company”), a leading advanced nuclear energy and technology company focused on developing clean energy solutions, today announced that Chief Executive Officer James Walker will participate in a fireside chat at H.C. Wainwright’s Powering the Future: Advancing Innovation Through Nuclear Virtual Conference hosted by Sameer Joshi, Senior Cleantech Analyst at H.C. Wainwright, on July 15, 2025 at 9:00 a.m., Eastern time.

The Special Purpose Vehicle will enable acceleration of public EV charging infrastructure, leveraging support from the LEVI initiative. 

DUBLIN, July 10, 2025 (GLOBE NEWSWIRE) -- via IBN – Fusion Fuel Green PLC (Nasdaq: HTOO) (“Fusion Fuel” or the “Company”) today announced a 1-for-35 reverse share split (the “Reverse Share Split”) of the Company’s Class A Ordinary Shares by way of a share consolidation.

FREMONT, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that production shipments of its newest electric vehicle (EV) charger, the IQ^® EV Charger 2, have expanded across Europe to now include Greece, Romania, Ireland, and Poland. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. Additionally, in France, the IQ EV Charger 2 has received one of the country’s highest quality standards, the E.V. READY certification, and can now integrate with the “Linky” meter to enable dynamic load balancing for standalone charger installations.

Together for Texas directly supports flood relief efforts in Texas through The Salvation Army

NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), will present new findings at the upcoming Alzheimer's Association International Conference (AAIC®) 2025 in Toronto. The presentations include a cost savings analysis of the use of pTau217 as a screening tool in Acumen’s Phase 2 ALTITUDE-AD trial of sabirnetug as well as a nonclinical study evaluating the relative selectivity of sabirnetug to targeting AβOs versus Aβ monomers. The conference will be held July 27-31, 2025, both in-person and online.